DUBAI, United Arab Emirates, Jan. 09, 2026 (GLOBE NEWSWIRE) — Presales rarely stay quiet once momentum builds. When demand keeps rising across multiple stages, later phases tend to move faster and attract more attention. That is exactly what is happening with Mutuum Finance (MUTM). Since early 2025, the project has recorded steady growth rather than […]
(NASDAQ:CCBG), TALLAHASSEE, Fla., Jan. 09, 2026 (GLOBE NEWSWIRE) — Capital City Bank Group, Inc. (NASDAQ: CCBG) announced today that it will release fourth quarter and year-end 2025 results on Tuesday, January 27, 2026, before the market opens. Upon release, investors may access a copy of the earnings results at the Company's Investor Relations website, investors.ccbg.com.
(NASDAQ:TLSA), BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Chief Executive Officer Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum, organized by Sachs Associates. The presentation
ADELAIDE, Australia, Jan. 09, 2026 (GLOBE NEWSWIRE) — Avance Clinical, the award-winning Australian led, global CRO built exclusively to service the clinical research needs of biotech companies, announced today that its executive team will attend Biotech Showcase 2026 in San Francisco, January 12-14, to meet with innovative biotech sponsors and highlight the company's newly launched
(NASDAQ:IMCR), Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US community and global market penetration Enrolling three Phase 3 trials across multiple melanoma indications – TEBE-AM enrollment completion anticipated 1H 2026; topline data expected as early as 2H 2026
PRESS RELEASE Memo Therapeutics AG Publishes BKPyV Infection Disease Burden Study in the Journal of Patient-Reported Outcomes First conceptual model demonstrating the impact of BK polyomavirus on the health-related quality of life of kidney transplant recipients Study conducted in partnership with Northwestern University and presented at the World Transplant Congress in August 2025 Schlieren /
CoinUp Announces Release Of Its 2025 Report Card: From Growth to Compliance, the Rise of Second-Tier Exchanges GlobeNewswire January 09, 2026 SINGAPORE, Jan. 09, 2026 (GLOBE NEWSWIRE) — CoinUp announced the release of its 2025 Report Card, detailing a year of accelerated user growth, strengthened regulatory compliance, disciplined product execution, and expanding global presence. As
— The second tranche of the share buyback is expected to be executed by May 8, 2026 — The share buyback program with a total volume of EUR 1 billion is expected to be completed in less than a year, significantly earlier than originally planned Fresenius Medical Care (FME), the world’s leading provider of products
Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for demyelinating diseases, today announced that it closed its Series A Extension Round of CAD$10 million from current investors CTI Life Sciences, Investissement Québec and adMare BioInnovations. The financing follows the successful completion of a Phase I clinical trial in healthy subjects
Retailer finalizes sale to iHerb The Kroger Co. (NYSE: KR) today announced the sale of its subsidiary, Vitacost.com, Inc., an eCommerce retailer of health and wellness products, to iHerb. The transaction closed on January 8. “As we shared earlier this fiscal year, we are reviewing all non-core assets to determine their ongoing contribution and role